Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05051930
Other study ID # TQC3721-I-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 18, 2021
Est. completion date December 31, 2022

Study information

Verified date October 2021
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Weimin Li, Post Doctor
Phone 028-85423837
Email llllllv2@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD)and asthma.


Recruitment information / eligibility

Status Recruiting
Enrollment 114
Est. completion date December 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the test; - Able to complete the study according to the requirements of protocol; - Aged between 18 and 65 years old, both men and women; - For healthy subjects: Male =50kg, female =45kg,body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value); For patients: BMI is 18-28 kg/m2 (including the critical value), and body weight is =45kg. - For healthy subjects: normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance; - For healthy subjects: FEV1 and forced vital capacity(FVC) are at least 90% of the predicted values; - Subjects (including male subjects) have no pregnancy plan and have voluntarily taken effective contraceptive measures for at least 1 month after being screened to the last use of the study drug; - For patients: Vital signs range: systolic blood pressure 90 to 140mmHg, diastolic blood pressure 50 to 90 mmHg, heart rate 50 to 90 bpm; - For patients: 12-lead electrocardiogram with QT interval corrected =450 msec (males) or =470 msec (females), QRS interval =120 msec, PR interval =200 msec and no morphologic and other clinical significant abnormalities (such as left band branch block, atrioventricular node dysfunction, ischemic ST segment abnormalities); - For patients: Ability to perform acceptable and reproducible spirometry; - For patients: According to the diagnostic criteria of 2018 Practical Edition of Guidelines for the Diagnosis and Treatment of COPD, the patient was diagnosed with COPD for at least 1 year;Post-bronchodilator spirometry at screening must demonstrate FEV1/FVC ratio of =0.70 and FEV1 must be =40 % to =80% of predicted normal; - For patients: mMRC Scoring at screening =2; - For patients: Clinically stable COPD in the previous 4 weeks; - For patients: Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication; - For patients: Current and former smokers with a smoking history of =10 pack years(smoking at least 20 cigarettes a day for 10 years or at least 10 cigarettes a day for 20 years); - For patients: beta agonists are currently used only "when needed"; - For patients: Never smoked or An ex-smoker for =6 months; Exclusion Criteria: - Preexisting or existing the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, immune system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator assesses that may affect drug metabolism or safety. - For healthy subjects: Have a history of fainting needles, fainting blood. - For healthy subjects: Known allergy to the study drug and their metabolites or any of the excipients of the formulation. - For healthy subjects: Those who smoked more than 5 cigarettes per day during the 3 months before the trial. - A history of alcohol abuse in the past 6 months (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine). - For healthy subjects: Donated blood or had substantial loss of blood (more than 400 mL) within 2 months before the test. - For healthy subjects: Had taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug. - Participated in other clinical trials within 3 months prior to this study. - Positive for hepatitis (including hepatitis B and C), human immunodeficiency virus(HIV) or syphilis at screening. - Women who are pregnant or breast-feeding. - Positive test for alcohol. - For healthy subjects: Blood collection is difficult or cannot tolerate venipuncture blood collection. - For healthy subjects: The subject is unable or can not comply with ward management regulations. - For healthy subjects: The subject is unable to complete the study due to personal reasons. - For healthy subjects: Any circumstances that the investigator considers to pose a safety risk to the subject during the study or may interfere with the conduct of the study. - For patients: Intolerance to salbutamol, tiotropium, or this product or prior exposure to Ensifentrine (RPL554). - For patients: Use of any medicine within 4 weeks prior to initiation of the study drug, including non-prescription medications and herbs, except vitamins. - For patients: Physical examination findings that researchers consider clinically significant at the time of screening. - For patients: A history of cardiovascular disease (including arrhythmias) or active hyperthyroidism. - For patients: History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQC3721 suspension for inhalation
Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
TQC3721 suspension placebo for inhalation
Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .

Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse events The Number of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 From the enrollment of the subjects to 72 hours after the last administration
Primary Incidence of adverse events The Incidence of adverse events as assessed by CTCAE v5.0 From the enrollment of the subjects to 72 hours after the last administration
Primary Number of adverse events related to the study drug The number of adverse events associated with the study drug assessed by CTCAE V5.0 From the enrollment of the subjects to 72 hours after the last administration
Primary Incidence of adverse events associated with the study drug Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0 From the enrollment of the subjects to 72 hours after the last administration
Primary Area Under The Curve(AUC) Area under the curve Within 60 minutes before each administration, to 72 hours after administration
Primary Plasma drug peak concentration(Cmax ) Plasma drug peak concentration Within 60 minutes before each administration, to 72 hours after administration
Primary Time to peak(Tmax) Time to maximum concentration following drug administration Within 60 minutes before each administration, to 72 hours after administration
Secondary Elimination half-life time(t1/2) Apparent terminal elimination half-life following drug administration Within 60 minutes before each administration, to 72 hours after administration
Secondary Apparent volume of distribution(Vd) Apparent volume of distribution Within 60 minutes before each administration, to 72 hours after administration
Secondary Clearance(CL) Clearance Within 60 minutes before each administration, to 72 hours after administration
Secondary Forced Expiratory Volume in the first second (FEV1) for patients with Chronic Obstructive Pulmonary Disease(COPD) or asthma Mean Change From Baseline in Peak FEV1 (Over 3 Hours) From before administration to 3 hours after administration
Secondary Mean Change From Baseline FEV1 to Morning Trough FEV1 Mean Change From Baseline FEV1 to Morning Trough FEV1 From the enrollment of the subjects to to 72 hours after administration
Secondary Mean Change From Baseline FEV1 to Average FEV1 Mean Change From Baseline FEV1 to Average FEV1 From the enrollment of the subjects to to 72 hours after administration
Secondary COPD Assessment Test (CAT) for patients with COPD Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week 4.The score range is 0 to 40 (0 to 10 is minor influence;11 to 20 is moderate; 21 to30 is severe;31 to 40 is very severe), and more than 10 indicates more symptoms. From enrollment to 4 weeks after administration
Secondary Modified medical research council(mMRC) for patients with COPD or asthma Mean Change From Baseline in mMRC Scoring at Week 4.The severity is measured on a five-point scale from 0 to 4, with a higher score indicating more severe respiratory distress. From enrollment to 4 weeks after administration
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy